carboplatin-paclitaxel-bevacizumab regimen
Term · Oncology and biomedicine · MLC-T-ONC-001417
A chemotherapy combination used to treat advanced, nonsquamous non-small cell lung cancer. It includes the drugs carboplatin, paclitaxel (Taxol), and bevacizumab. Also called carboplatin-Taxol-bevacizumab regimen.
| Identifier | MLC-T-ONC-001417 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | carboplatin-Taxol-bevacizumab regimen |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-001417",
"term": "carboplatin-paclitaxel-bevacizumab regimen",
"field": "Oncology and biomedicine",
"definition": "A chemotherapy combination used to treat advanced, nonsquamous non-small cell lung cancer. It includes the drugs carboplatin, paclitaxel (Taxol), and bevacizumab. Also called carboplatin-Taxol-bevacizumab regimen.",
"synonyms": [
"carboplatin-Taxol-bevacizumab regimen"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/carboplatin-paclitaxel-bevacizumab-regimen/"
}
Record 4,205 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.